Research programme: tyrosine kinase inhibitors - Kyowa Kirin
Alternative Names: Ki 11502; Ki 23057; KRN-383Latest Information Update: 16 Jul 2019
At a glance
- Originator Kirin Brewery
- Class Quinolines
- Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan (PO)
- 06 Apr 2011 Pharmacodynamics data from preclinical trials in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR-2011)
- 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin